Introduction
The ErbB family of receptor tyrosine kinases includes the epidermal growth factor receptor (EGFR, ErbB) and the closely related ErbB2 (HER2/Neu), ErbB3 (HER3) and ErbB4 (HER4) proteins (Hynes and MacDonald, 2009 ). They share a common molecular architecture and consist of a glycosylated extracellular ligand binding domain, a single transmembrane region and a cytoplasmic domain with tyrosine kinase activity (Yarden and Sliwkowski, 2001) . Ligand binding and receptor dimerization stimulate the receptors' intrinsic tyrosine kinase activity, which results in autophosphorylation of specific tyrosine residues within the cytoplasmic domain. These serve as docking sites for intracellular substrates and adapter proteins that initiate signaling cascades affecting cell growth, survival and differentiation. Aberrant activation by mutation or overexpression of ErbB receptors and their ligands has been found in many human cancers of various origins, and has been implicated in cancer pathogenesis (Hynes and MacDonald, 2009) .
Targeted therapeutics specifically inhibiting ErbB receptors have been developed and introduced successfully into clinical practice. Monoclonal antibodies (mAbs) that bind to the extracellular domain of EGFR or ErbB2, and small molecular weight compounds that inhibit the receptors' tyrosine kinase activity, can inhibit tumor growth and result in a survival benefit for cancer patients (Groner et al., 2004; Hynes and Lane, 2005; Mendelsohn and Baselga, 2006) . Different modes of action have been described for the inhibitory activity of ErbB-specific antibodies, which are determined by their corresponding epitopes (Leahy, 2008) . Cetuximab (Erbitux) is a chimerized anti-EGFR antibody that contains heavy and light chain variable domains of the murine mAb 225 (Sato et al., 1983; Goldstein et al., 1995) , and matuzumab (EMD72000) is a fully humanized derivative of the murine mAb 425 (Murthy et al., 1987; Kettleborough et al., 1991) . Both antibodies bind to ectodomain III of EGFR in its autoinhibited conformation and prevent ligand-induced activation of the receptor. Cetuximab directly blocks residues important for EGF binding (Li et al., 2005) . Matuzumab binds to an epitope not overlapping with the ligand binding site, but sterically prevents conformational changes within EGFR required for high-affinity ligand binding and receptor dimerization (Schmiedel et al., 2008) .
In view of the success of passive cancer immunotherapy with mAbs, it appears desirable to expand treatment options by induction of functionally similar endogenous antibody responses. In the case of cetuximab and matuzumab this is complicated by their conformational epitopes, which comprise residues that are separated in the primary sequence but assembled on the surface of the folded EGFR ectodomain III (Li et al., 2005; Schmiedel et al., 2008) . Hence, peptide mimotopes that mimic structural features of the epitopes recognized by mAbs may be suitable alternatives as antigens for the induction of equivalent endogenous immune responses (Partidos, 2000; Riemer et al., 2004 Riemer et al., , 2005 .
Here we describe novel peptide sequences that are specifically recognized by the anti-EGFR antibodies cetuximab and matuzumab. The peptides were selected from phage-displayed random peptide libraries by delayed infectivity panning (Benhar et al., 2000) using Escherichia coli cells that carry single-chain Fv (scFv) antibody fragments of cetuximab and matuzumab on their surface. Comparison of the selected peptides revealed several common sequence motifs not related to the primary amino-acid sequence of EGFR. Despite the different localization and composition of the EGFR epitopes reported for cetuximab and matuzumab, two of these motifs characterized by KTL and YPLG sequences were recognized equally well by both mAbs, and induced endogenous antibodies in rabbits crossreactive with EGFR. Furthermore, the anti-peptide antibodies prevented binding of natural EGFR ligands, ligand-induced receptor activation and growth of tumor cells in a manner similar to cetuximab and matuzumab. Thus, the selected peptides can serve as a basis for the development of immunogens that induce endogenous antagonistic anti-EGFR antibodies, and may therefore have important implications for cancer immunotherapy.
Results
Selection of peptide-displaying phage that interact with cetuximab and matuzumab Phage displaying peptides that specifically interact with cetuximab or matuzumab were selected by delayed infectivity panning (Benhar et al., 2000) from libraries of M13KE bacteriophage that display randomized linear 7mer, linear 12mer or cyclic 7mer peptides. For screening, we used noninfectable F À E. coli HB101 cells carrying single-chain antibody fragments (scFv) scFv(225) of cetuximab (Wels et al., 1995) or scFv(72000) of matuzumab as Lpp-OmpA' fusions (Georgiou et al., 1997) on the surface as schematically shown in Figures 1a and b . After removal of unbound phage particles, bound phage were amplified by adding infectable F þ E. coli ER2738. During three rounds of selection we observed an increase in the ratio of output to input titers indicating enrichment of specifically bound phage (Figure 1c) . Specificity of pIII fusion peptides displayed by individual phage clones from the enriched pools for cetuximab or matuzumab was confirmed by enzyme-linked immunosorbent assay (ELISA) with immobilized full-length antibodies. Thereby some phage clones showed enhanced binding to both target antibodies (see Supplementary Figure 1 ).
Peptides containing KTL or YPLG motifs bind to cetuximab and matuzumab Sequence analysis revealed several short peptide motifs common to two or more phage clones selected independently from different phage libraries for each antibody target. Peptides containing KTL or YPLG motifs were found both among phage selected with scFv(225) and scFv(72000), suggesting that these sequences may define common peptides recognized by both antibodies (Table 1) . To investigate this further, we analyzed the ability of the phage clones to interfere with cell binding and cytotoxic activity of the EGFR-specific antibody-toxin scFv(225)-ETA that carries the binding domain of cetuximab fused to truncated Pseudomonas exotoxin A (ETA) (Wels et al., 1995; Azemar et al., 2000) . EGFR-expressing Renca-lacZ/EGFR renal carcinoma cells (Schmidt et al., 1999) were treated with scFv(225)-ETA after preincubation of antibody-toxin with a 10-fold molar excess (based on pIII fusion peptides present) of phage before cell killing was determined in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assays. Although control phage did not inhibit cell binding of scFv(225)-ETA resulting in more than 60% cell killing at the chosen conditions, cetuximab and all tested phage showing KTL-or YPLG-containing peptides efficiently Figure 1 Selection of cetuximab-and matuzumab-binding peptide-displaying phage by delayed infectivity panning. Expression of scFv antibody fragments as Lpp-OmpA' fusion proteins on the surface of E. coli (a). Anti-EGFR scFv antibody fragments scFv(225) of cetuximab, or scFv(72000) of matuzumab, were fused to signal peptide and amino acids 1-9 of the E. coli major outer membrane lipoprotein (Lpp) and residues 46-159 of the outer membrane protein OmpA (OmpA') in plasmid pIB-Tx. Upon bacterial expression under the control of an IPTG-inducible lpp-lac promoter, the Lpp-OmpA'-scFv fusion proteins are anchored in the outer membrane of E. coli as schematically shown in (b). Enrichment of scFv-binding peptide-displaying phage by delayed infectivity panning (c). Phage binding to scFv fragments of cetuximab or matuzumab were selected in independent sets of experiments from libraries of M13KE bacteriophage displaying randomized linear 7mer, linear 12mer or cyclic 7mer (C7C) peptides using IPTG-induced cultures of E. coli HB101 harboring pIB-Tx-scFv(225) or pIB-Tx-scFv(72000).
prevented intoxication of cells (see Supplementary  Figure 2a ). This effect was specific for scFv(225)-ETA, as neither cetuximab nor peptide-displaying phage were able to inhibit cytotoxic activity of an ErbB2-specific antibody-toxin against ErbB2-expressing Renca-lacZ/ ErbB2 cells (Wels et al., 1992; Maurer-Gebhard et al., 1998; see Supplementary Figure 2b) .
Interaction of cetuximab and matuzumab with KTLor YPLG-containing sequence motifs was analyzed further with peptide arrays carrying the selected peptides in synthetic form (Figure 2a ). With the exception of the fusion peptide of phage 225.1P-05 (see Table 1 ), cetuximab and matuzumab recognized all synthetic peptides representing the selected KTL-or YPLG-containing motifs (Figure 2a, left) . In contrast, the anti-EGFR antibodies failed to interact with nonrelated control peptides and the phage-encoded GGGS linker sequence present in all selected peptides (Figure 2a, right) . ErbB2-specific mAb trastuzumab included as an additional control did not bind to any of the peptides on the array. The peptide array analysis also revealed that in surfacebound form the short 4mer and 3mer sequences YPLG and KTL on their own failed to interact with cetuximab and matuzumab, but required for binding the context of the variable surrounding sequences, which may contribute flexibility (Figure 2a, right) .
We chose representative KTL-and YPLG-containing peptides selected with scFv(72000) but cross-reactive with scFv(225) for further analysis. To confirm competition of scFv(225) binding, we included synthetic peptides VLPKTLCGGGS representing the linear 7mer KTL motif and adjacent linker region from phage E72.3A, or ACKYPLGHQCGGGS representing the cyclic 7mer YPLG motif and surrounding residues from phage E72.C4 (Table 1) as competitors in a cell-killing assay with scFv(225)-ETA. Both peptides efficiently inhibited cytotoxicity of the antibody-toxin, confirming the data obtained with the corresponding phage (Figure 2b) .
Binding of cetuximab and matuzumab to the synthetic KTL-and YPLG-containing peptides VLPKTLCGGGS and ACKYPLGHQCGGGS was quantified by ELISA ( Figure 2c ). We observed saturable binding of both anti-EGFR antibodies to both peptides, but no binding of the anti-ErbB2 antibody trastuzumab was found. Apparent affinities were determined from the resulting binding curves by nonlinear regression revealing K D values of 1.2 Â 10 À6 ± 5.8 Â 10 À7 M and 1.3 Â 10
for binding of matuzumab to VLPKTLCGGGS and ACKYPLGHQCGGGS, respectively. K D values for binding of cetuximab to VLPKTLCGGGS and ACK-YPLGHQCGGGS were 1.2 Â 10 À6 ± 5.2 Â 10 À7 M and 1.2 Â 10 À6 ±5.3 Â 10 À7 M, respectively. Hence, both matuzumab and cetuximab bind with very similar affinities to the peptides selected with scFv(72000) of matuzumab, further confirming cross-reactivity.
Anti-peptide antibodies bind to EGFR
The KTL-or YPLG-containing peptides did not reveal any obvious homologies with the linear amino-acid sequence of human EGFR. Nevertheless, they could mimic structural determinants on the surface of EGFR that partly overlap with the conformational epitopes recognized by matuzumab and cetuximab (Li et al., 2005; Schmiedel et al., 2008) . To investigate whether antibodies raised against these peptides cross-react with EGFR, we immunized rabbits with synthetic peptides VLPKTLCGGGS (KTL motif) and ACKYPLGH QCGGGS (YPLG motif), and specifically binding anti-peptide antibodies were affinity purified from sera. We then tested reactivity of the antibodies with human EGFR. In immunofluorescence experiments binding of anti-KTL peptide antibodies to the surface of RencalacZ/EGFR cells was detected, which was very similar to that observed with matuzumab ( Figure 3a ). No such binding was detected with pre-immune serum or with anti-KTL peptide antibodies preincubated with an excess of VLPKTLCGGGS peptide, confirming specificity. Similar results were obtained with anti-YPLG peptide antibodies (Figure 3b ).
To confirm interaction with EGFR, we analyzed binding of anti-peptide antibodies to Renca-lacZ/EGFR cells by flow cytometry. Although no binding was detected with pre-immune serum, anti-KTL and anti-YPLG peptide antibodies specifically bound to the surface of Renca-lacZ/EGFR, but not EGFR-negative Renca-lacZ cells (see Supplementary Figure 3a) . Likewise, cetuximab and matuzumab only bound to the surface of Renca-lacZ/EGFR cells, whereas anti-ErbB2 antibody trastuzumab did not bind to either cell line. Peptide mimotopes induce anti-EGFR antibodies C Hartmann et al Figure 2 Binding of mAbs cetuximab and matuzumab to peptide arrays (a). Left: Peptides representing the indicated KTL-or YPLGcontaining sequence motifs of selected phage clones were synthesized on cellulose membranes by automated parallel peptide synthesis. Membranes were incubated with cetuximab, matuzumab or ErbB2-specific trastuzumab as a control, and binding was analyzed with anti-human IgG/HRP and chemiluminescent detection. Right: To confirm specificity, we performed a similar experiment including peptides ACKYPLGHQCGGGS (YPLG motif from phage E72.C4), VLPKTLCGGGS (KTL motif from phage E72.3A), irrelevant control peptides LPASPETHL and SFLQDIQEV, the GGGS linker sequence or isolated YPLG and KTL sequences. Exposure times for chemiluminescent detection were 1 min (cetuximab and matuzumab) and 5 min (trastuzumab). Inhibition of cell killing by EGFRspecific scFv(225)-ETA antibody-toxin by synthetic peptides containing KTL or YPLG sequence motifs (b). Left: Triplicate samples of EGFR-expressing Renca-lacZ/EGFR renal carcinoma cells were treated with scFv(225)-ETA antibody-Pseudomonas exotoxin A fusion protein after preincubation of antibody-toxin with a 100-fold molar excess of synthetic peptides VLPKTLCGGGS (KTL motif) or ACKYPLGHQCGGGS (YPLG motif) as described in Supplementary Methods. Control cells were treated without antibody-toxin, with toxin without competitor (PBS) or with the irrelevant peptide SFLQDIQEV (control) as competitor. Right: Specificity was confirmed in similar experiments with ErbB2-specific scFv(FRP5)-ETA antibody-toxin and ErbB2-expressing Renca-lacZ/ErbB2 cells. The relative number of viable cells was determined after 48 h in MTT cell viability assays. Representative data from one of two independent experiments are shown. Statistically significant differences are indicated. ***P o0.001; NS, P40.05. Data are represented as mean±s.d. Binding of mAbs cetuximab and matuzumab to synthetic peptides VLPKTLCGGGS (left) and ACKYPLGHQCGGGS (right) was measured by ELISA by adding serial dilutions of cetuximab, matuzumab or anti-ErbB2 mAb trastuzumab as control to triplicate samples of immobilized peptides (c). Data are represented as mean ± s.d.
Peptide mimotopes induce anti-EGFR antibodies C Hartmann et al
To show colocalization with EGFR, we incubated Renca-lacZ/EGFR cells simultaneously with antipeptide antibodies and murine anti-EGFR antibody R1. R1 recognizes an epitope within the extracellular domain of human EGFR distinct from the binding sites of cetuximab and matuzumab (Waterfield et al., 1982; Cochran et al., 2004) . Binding was visualized by immunofluorescence and confocal laser scanning microscopy. Both anti-KTL and anti-YPLG peptide antibodies co-localized with antibody R1 (Figure 3b ), confirming specific interaction with EGFR. Furthermore, in immunoblot experiments anti-KTL and anti-YPLG peptide antibodies detected EGFR in lysates of EGFR-overexpressing A431 and Renca-lacZ/EGFR cells, whereas no such band was detected in lysates of SK-OV-3 ovarian carcinoma cells that express EGFR at a level below the detection limit of the experiment (see Supplementary Figure 3b ). (Figure 3c ). Inhibition of ligand-dependent activation of EGFR is a hallmark of the activities of both cetuximab and matuzumab. To investigate whether binding of antipeptide antibodies to EGFR affects ligand-induced receptor activation, we pretreated serum-starved A431 cells with anti-KTL or anti-YPLG peptide antibodies before stimulation with EGF. EGFR autophosphorylation as a measure of receptor activation was determined by immunoblot analysis. Although phosphorylated EGFR was readily detected in EGF-stimulated cells in the absence of inhibitory antibody, cetuximab and matuzumab blocked receptor activation. Likewise, both Then cells were stimulated with 50 ng/ml EGF (lanes 2-6) for 10 min, cell lysates were prepared and analyzed by SDS-PAGE and immunoblotting with anti-phosphotyrosine antibody followed by HRP-conjugated secondary antibody and chemiluminescent detection (upper panel). Total EGFR was analyzed with anti-EGFR antibody (lower panel). Inhibition of cell killing by recombinant TGFa-ETA ligand-toxin by anti-peptide antibodies (b). Triplicate samples of A431 cells were pretreated for 30 min with 1 mg/ml matuzumab, anti-KTL or anti-YPLG peptide antibodies before addition of 50 ng/ml of recombinant TGFa-ETA ligand-toxin. Control cells were treated without ligand-toxin, or pretreated with PBS or pre-immune serum as indicated. The relative number of viable cells was determined after 48 h in MTT cell viability assays. Representative data from one of two independent experiments are shown. Statistically significant differences are indicated. ***Po0.001; **Po0.01; NS, P40.05. Data are represented as mean±s.d. Inhibition of tumor cell growth by anti-peptide antibodies (c). Triplicate samples of A431 and MDA-MB468 cells were incubated with 50 mg/ml of anti-KTL or anti-YPLG peptide antibodies, or matuzumab, trastuzumab or pre-immune serum as indicated. The relative number of viable cells in comparison to PBS-treated controls was determined after 70 h in MTT cell viability assays. Representative data from one of two independent experiments are shown. Statistically significant differences between PBS-treated group and groups treated with antibodies are indicated. ***Po0.001; **Po0.01; NS, P40.05. Data are represented as mean±s.d.
anti-KTL and anti-YPLG peptide antibodies markedly reduced EGF-induced EGFR autophosphorylation (Figure 4a ). In a separate experiment, we also investigated the influence of anti-peptide antibodies on the binding of TGFa to EGFR-expressing cells using the cytotoxic activity of the ligand-toxin TGFa-ETA as a sensitive readout. Similar to scFv(225)-ETA described above, TGFa-ETA is an EGFR-specific fusion toxin containing truncated Pseudomonas ETA, but using residues 1-50 of human TGFa for target cell binding (Schmidt and Wels, 1996) . A431 cells were pretreated with anti-peptide antibodies, or pre-immune serum or matuzumab as controls, before addition of TGFa-ETA and determination of the relative number of viable cells. Matuzumab was the most potent competitor in this assay and completely prevented cell killing (Figure 4b ). Also anti-KTL (16% versus 85% cell killing in the absence of competitor) and anti-YPLG antibodies (43% cell killing) markedly reduced intoxication of cells by TGFa-ETA, whereas pre-immune serum did not significantly affect TGFa-ETA cytotoxicity (76% cell killing).
To test whether antibody-mediated inhibition of ligand binding and EGFR activation can affect tumor cell growth, we investigated anchorage-dependent growth of human A431 and MDA-MB468 cancer cells. These cells overexpress EGFR and produce TGFa in an autocrine manner. Treatment with anti-KTL or anti-YPLG peptide antibodies resulted in growth inhibition of both cell lines, which was more pronounced than inhibition by matuzumab (Figure 4c ). In the case of A431 cells, 50 mg/ml of anti-KTL peptide antibody Figure 5 Potential epitopes for anti-peptide antibodies are located on the surface of domain III of EGFR. Surface representation of EGFR domain III (a). Amino-acid residues that interact with cetuximab, EGF or both cetuximab and EGF, or matuzumab are represented in color as indicated. EGFR regions defined by residues F 352 P 349 V 350 G 354 with similarity to the YPLG motif (left), and G 410 H 409 Q 408 homologous to the adjacent sequence of peptides displayed by matuzumab-binding phage E72.4A and E72.C4 (right) are highlighted in red (b). EGFR regions defined by residues K 463 T 464 I 466 (left) and K 465 T 464 I 466 (right) with similarity to the KTL motif are highlighted in red (c). Results were visualized using EGFR X-ray crystal structure data from PDB ID 1YY9.
Peptide mimotopes induce anti-EGFR antibodies C Hartmann et al reduced growth to 31%, and anti-YPLG peptide antibody reduced growth to 39% in comparison to phosphate-buffered saline (PBS)-treated controls (Po0.01). Although under the chosen conditions matuzumab also inhibited A431 cell growth (63%), this effect was not statistically significant (P40.05). In the case of MDA-MB468 cells anti-KTL peptide antibody reduced growth to 44%, anti-YPLG peptide antibody to 49% and matuzumab to 62% in comparison to PBS-treated controls (Po0.001). ErbB2-specific antibody trastuzumab and pre-immune serum had no significant effects on the growth of either cell line. Taken together, these data show that anti-KTL and anti-YPLG peptide antibodies share important functional characteristics of cetuximab and matuzumab. They block ligand binding and activation of EGFR, and inhibit anchorage-dependent growth of EGFR-overexpressing cancer cells.
Potential EGFR epitopes recognized by anti-peptide antibodies
To examine whether the extracellular domain of EGFR carries conformational sequence motifs on the surface that are similar to the KTL-and YPLG-containing peptides, we performed in silico epitope mapping (Mayrose et al., 2007a, b) with EGFR X-ray crystal structure data of the complete EGFR extracellular domain from PDB ID 1YY9 as a source (Li et al., 2005;  Figure 5a) . A search for conformational sequence motifs with similarity to YPLG-containing peptides yielded two regions on the surface of EGFR ectodomain III defined by F 352 P 349 V 350 G 354 , which is directly adjacent to the cetuximab binding site reported by Li et al. (2005) , and G 410 H 409 Q 408 , which partly overlaps with the reported cetuximab binding site in an area close to residues recognized by matuzumab (Figure 5b) . A GHQ motif is part of the YPLG-containing peptides displayed by phage E72.4A and E72.C4 (Table 1) , the latter of which was used as the YPLG motif for immunization of rabbits.
Mapping of KTL-containing peptides revealed two areas with similarity to KTL (K 463 T 464 I 466 and K 465 T 464 I 466 ), both of which are located on the surface of EGFR ectodomain III at the interface between the reported epitopes of cetuximab and matuzumab (Figure 5c ). Interestingly, in the published structures K 463 is in direct contact with matuzumab (Schmiedel et al., 2008) , whereas K 465 is important for binding of both cetuximab and EGF (Ogiso et al., 2002; Li et al., 2005) .
Discussion
We investigated cetuximab-and matuzumab-binding peptides selected from random peptide libraries for their ability to mimic EGFR determinants recognized by these therapeutic antibodies. For peptide selection, we used delayed infectivity panning (Benhar et al., 2000) , which was based on the display of scFv antibody fragments of cetuximab and matuzumab on the surface of E. coli cells. This allowed rapid isolation of specific binders, and was expected to restrict selected peptides to those that either interact directly with the antigen binding sites of the antibodies encompassing the complementarity determining regions of heavy and light chain variable domains, or bind to adjacent framework regions that provide structural stability. Phage pools selected from independent phage libraries all contained peptide-displaying clones that bound strongly to intact antibodies corresponding to the scFvs used for screening. Interestingly, although selected with an individual scFv antibody fragment, some phage clones characterized by KTL or YPLG motifs bound to both cetuximab and matuzumab. Peptide array analysis with synthetic peptides confirmed specific interaction of the selected fusion peptides with the anti-EGFR antibodies. Nevertheless, to be recognized by cetuximab and matuzumab, surface-bound KTL and YPLG motifs required the context of their variable surrounding sequences, which possibly contribute flexibility.
Two representative KTL-or YPLG-containing peptides selected with the scFv fragment of matuzumab but cross-reactive with cetuximab were chosen for detailed analysis. Both peptides were bound by cetuximab and matuzumab in saturation ELISA with similar micromolar apparent affinities, and induced antibodies in rabbits that cross-reacted with human EGFR. Importantly, these anti-peptide antibodies shared functional characteristics with cetuximab and matuzumab, which are crucial for the antitumoral activity of the therapeutic antibodies. The anti-peptide antibodies markedly inhibited EGF-dependent activation of EGFR, blocked binding of TGFa to the receptor and inhibited anchorage-dependent growth of EGFR-overexpressing cancer cells. These data indicate that the selected peptides mimic structural features of EGFR, and strongly argue for structural similarities of the peptides with parts of the conformational EGFR epitopes recognized by cetuximab and matuzumab.
Although both cetuximab and matuzumab prevent ligand-induced activation of the receptor by binding to EGFR ectodomain III in its tethered, autoinhibited conformation, they have different mechanisms of action (Li et al., 2005; Schmiedel et al., 2008) . The binding site of cetuximab partly overlaps with EGFR residues important for interaction with EGF, resulting in direct competition of ligand binding (Li et al., 2005) . In contrast, matuzumab binds to a neighboring epitope not overlapping with the EGF binding site. Inhibition of ligand-induced EGFR activation by this antibody is explained by sterical hindrance of conformational changes within EGFR that are required for high-affinity ligand binding and receptor dimerization (Schmiedel et al., 2008) . X-ray crystallographic data of the Fab fragments of cetuximab and matuzumab in complex with the entire extracellular domain of EGFR or EGFR ectodomain III revealed adjacent, but nonoverlapping epitopes for the antibodies which may allow simultaneous binding (Li et al., 2005; Schmiedel et al., 2008) . Hence, the observed cross-reactivity of KTL-and YPLG-containing peptides with cetuximab and matuzumab was unexpected. Although it may be explained simply by incidental structural similarities of the peptides with distinct regions in EGFR ectodomain III independently recognized by the therapeutic antibodies, it is intriguing that in silico analysis of similarities between the peptides and residues on the surface of EGFR identified possible motifs close to the reported binding sites of cetuximab and matuzumab.
In the phage-displayed and synthetic peptides these motifs can be expected to be less constrained than in the context of EGFR ectodomain III, and the sequences may adopt a structure fitting the surface of cetuximab and matuzumab well enough for binding with the observed micromolar affinity. In this regard it is interesting to note that the respective regions of EGFR ectodomain III adopt slightly different structures depending on the antibody bound (Li et al., 2005; Schmiedel et al., 2008) , which also affects the relative positions of the KTL-like motifs. This could indicate that in solution cetuximab and matuzumab are able to interact with epitopes that partially overlap and extend beyond the contact regions identified by X-ray crystal structure analysis (Li et al., 2005; Schmiedel et al., 2008) . Occupation of this EGFR region by the anti-peptide antibodies can explain the observed partial competition of cetuximab and matuzumab, and the inhibition of EGF-dependent receptor activation and TGFa binding. Hence, this EGFR region may define an interesting alternative structure for specific targeting by therapeutic antibodies. Although anti-peptide antibodies blocked ligand binding to EGFR to a lesser extent than cetuximab and matuzumab, their inhibitory effect on tumor cell growth was more pronounced than that of matuzumab. This could, in part, be due to the polyclonal nature of the affinity-purified anti-peptide antibodies, which may still contain multivalent IgM in addition to IgG, possibly resulting in enhanced EGFR downregulation.
In clinical studies prolonged treatment with cetuximab or matuzumab has generally been well tolerated, with skin reactions such as an acne-like rash being the most common side effect (Baselga et al., 2005; Rao et al., 2008; Seiden et al., 2007) . Furthermore, endogenous humoral and cellular anti-EGFR immune responses have been observed in cancer patients (Shomura et al., 2004) , suggesting that limited autoimmunity to EGFR is acceptable. For active EGFRtargeted cancer immunotherapy, vaccines that direct the induced immune response to antibodies blocking a defined structure within EGFR that is important for signaling may be of particular advantage. Our data show that the peptide mimotopes selected with cetuximab and matuzumab indeed mimic important structural features of EGFR, and as immunogens induce antibodies in animals that cross-react with human EGFR, block ligand-induced receptor activation and inhibit tumor cell growth. Vaccines based on EGFR protein or EGFR-derived peptides must overcome immunological tolerance to this self-antigen. In contrast, the primary amino-acid sequences of the identified peptide mimotopes are unrelated to those of EGFR, and it is unlikely that their immunogenicity is affected by tolerance to EGFR. Although the potential of the selected peptide mimotopes to induce antibody responses also cross-reactive with self-EGFR remains to be investigated, they may serve as a starting point for further optimization and the development of EGFR-specific vaccines for active cancer immunotherapy.
Materials and methods
Delayed infectivity panning IPTG-induced F À E. coli HB101 cells carrying surface display vectors pIB-Tx-scFv(72000) or pIB-Tx-scFv(225) (see Supplementary Methods) were incubated for 20 min at room temperature with libraries of M13KE bacteriophage that display randomized linear 7mer (M13KE Ph.D.-7), linear 12mer (M13KE Ph.D.-12) or cyclic 7mer (M13KE Ph.D.-C7C) peptides (New England Biolabs, Schwalbach, Germany) using a constant phage input of 2 Â 10 11 plaque-forming units. Unbound phage were removed by extensive washing with PBS, 0.05% Tween-20, followed by PBS. Washed bacteria were mixed with tetracycline-resistant F þ E. coli ER2738 cells (New England Biolabs) for 30 min at 37 1C to allow infection by bound phage. Then pIB-Tx-scFv carrying E. coli HB101 were removed by adding 12.5 mg/ml tetracycline, and the remaining E. coli ER2738 were grown for 3 h at 37 1C in 20 ml LB medium for amplification of phage. Phage-containing supernatants were collected and subjected to negative selection by incubation for 20 min with unmodified E. coli HB101 cells. After three positive and negative selection rounds single-phage clones were isolated for sequencing of single-stranded DNA and functional analysis.
Binding of anti-EGFR antibodies to synthetic peptides Peptides on peptide arrays were synthesized by Fmoc chemistry at activated PEG spacers on cellulose membranes by automated parallel peptide synthesis on a MultiPep RS instrument (Intavis, Cologne, Germany) as described previously (Brandt et al., 2009) . Membranes were incubated with cetuximab, matuzumab or ErbB2-specific trastuzumab as a control. Bound primary antibodies were detected with antihuman IgG/HRP (Sigma-Aldrich, Deisenhofen, Germany) and chemiluminescent detection with the ECL kit. For ELISA experiments 96-well plates were coated overnight at 4 1C with 5 mg per well of synthetic peptides VLPKTLCGGGS (KTL motif from phage E72.3A) or ACKYPLGHQCGGGS (YPLG motif from phage E72.C4) in 0.1 M NaHCO 3 (pH 8.6). Remaining binding sites were blocked with 3% skim milk powder in PBS, and serial dilutions of mAbs cetuximab, matuzumab, or anti-ErbB2 mAb trastuzumab as control were added to triplicate samples. After incubation for 60 min at room temperature, wells were washed with PBS, and antihuman IgG/HRP (Sigma-Aldrich) was added for 30 min at room temperature. After another washing step with PBS, 100 ml/well ABTS horseradish peroxidase (HRP) substrate solution were added for 30 min at 37 1C before absorbance at 405 nm was measured using a microplate reader. Apparent affinities were determined from the resulting binding curves by nonlinear regression using GraphPad Prism 5 software (GraphPad Software).
Binding of anti-peptide antibodies to EGFR For immunofluorescence microscopy, Renca-lacZ/EGFR cells were incubated for 60 min on ice with polyclonal rabbit anti-peptide antibodies recognizing the selected peptides VLPKTLCGGGS or ACKYPLGHQCGGGS (see Supplementary Methods), pre-immune serum or matuzumab in PBS, 3% bovine serum albumin. For competition experiments, antipeptide antibodies pretreated with a 40-fold molar excess of specific peptide were used. For colocalization studies, cells were simultaneously incubated with anti-peptide antibodies or pre-immune serum and murine anti-EGFR mAb R1 (SigmaAldrich). After washing with PBS, cells were treated with antirabbit IgG/FITC (fluorescein isothiocyanate), anti-human IgG/FITC, anti-rabbit-PE (Sigma-Aldrich), anti-mouse IgG/ Alexa Fluor 488 (Invitrogen, Karlsruhe, Germany) or combinations thereof in PBS, 3% bovine serum albumin for 45 min at 4 1C in the dark. Cell bodies were visualized by staining with an excess of propidium iodide. Samples were analyzed with a Leica TCS SL laser scanning microscope (Leica Mikrosysteme, Bensheim, Germany) . To analyze competition of cetuximab and matuzumab binding to cells by anti-peptide antibodies, we pre-incubated Renca-lacZ/EGFR cells with a 20-fold molar excess of anti-peptide antibodies or pre-immune serum for 30 min on ice. Then flow cytometric analysis was performed with cetuximab and matuzumab followed by anti-human IgG/FITC (Dako, Glostrup, Denmark) using a FACScan cytometer and CellQuest Pro software (Becton Dickinson, Heidelberg, Germany).
Competition of ligand binding to EGFR A431 cells (ATCC) were grown overnight in medium containing low serum (1% fetal calf serum). Medium was removed, and cells were pretreated for 10 min at 37 1C with anti-peptide antibodies, mAbs cetuximab or matuzumab or PBS. For EGFR stimulation, 50 ng/ml human EGF (Sigma-Aldrich) was added for 10 min at 37 1C, followed by incubation in lysis buffer (50 mM Tris, 1% SDS, 5 mM EGTA, 150 mM NaCl, 100 mM Na 3 VO 4 , 1 mM PMSF (pH 7.2)) for 30 min on ice. Cell debris was removed by centrifugation, and cleared lysates were analyzed by SDSpolyacrylamide gel electrophoresis and immunoblotting with murine anti-phosphotyrosine antibody 2C8 (Santa Cruz Biotechnology, Heidelberg, Germany) or rabbit anti-EGFR antibody 15E (a kind gift from Dr N Hynes, Friedrich Miescher Institute, Basel), followed by HRP-conjugated secondary antibodies and chemiluminescent detection with the ECL kit. Recombinant TGFa-ETA Pseudomonas ETA fusion protein (Schmidt and Wels, 1996) was used to investigate competition of TGFa binding to EGFR. A431 cells were pretreated for 30 min with 1 mg/ml of matuzumab, anti-peptide antibodies, pre-immune serum or PBS as controls, before addition of 50 ng/ml of TGFa-ETA for 48 h at 37 1C and determination of the relative number of viable cells in MTT cell viability assays as described (Schmidt and Wels, 1996) .
Inhibition of tumor cell growth
Human A431 squamous cell and MDA-MB468 breast carcinoma cells (ATCC) were seeded in 96-well plates at a density of 2 Â 10 4 cells per well in the presence of 50 mg/ml of anti-peptide antibodies, or matuzumab, trastuzumab or pre-immune serum as controls. Cells were incubated for 70 h at 37 1C before the relative number of viable cells in comparison to cells grown without addition of antibodies was determined in MTT cell viability assays as described (Schmidt and Wels, 1996) .
Epitope prediction
Epidermal growth factor receptor sequence motifs accessible on the EGFR surface with similarity to the selected peptide sequences were identified using the Pepitope server (The George S Wise Faculty of Life Sciences, Tel-Aviv University) for epitope mapping of affinity-selected peptides employing the PepSurf algorithm (Mayrose et al., 2007a, b) . Results were visualized with Visual Molecular Dynamics molecular modeling software (Humphrey et al., 1996) using EGFR X-ray crystal structure data from PDB ID 1YY9 (Li et al., 2005) and 3C09 (Schmiedel et al., 2008) .
Statistical analysis
One-way ANOVA followed by Tukey's multiple comparison test was applied to assess statistical significance of differences between multiple treatment groups in competition experiments and analysis of tumor cell growth. Data were analyzed using GraphPad Prism 5 software.
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